Drug intelligence / Profile preview

SHR-1501 + SHR-2005

Development stage: Unknown
Lead developer: Hengrui Pharmaceutical
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Intravesical

Overview

SHR-1501 + SHR-2005 is an investigational combination therapy being developed for high-risk non-muscle invasive bladder cancer (HR NMIBC) that cannot be completely resected by transurethral resection of bladder tumor (TURBt). SHR-1501 is an IL-15 superagonist fusion protein that promotes immune response by enhancing the infiltration of CD8+ T cells, effector CD8+ T lymphocytes, and natural killer (NK) cells in the tumor microenvironment. SHR-2005 is administered via intravesical instillation directly into the bladder. The combination is being developed by Jiangsu Hengrui Medicine and is currently in clinical trials.

Targets

IL15RA (Interleukin-15 receptor subunit alpha)IL2RB (IL-2 receptor beta chain)

Beyond the preview

Go deeper on SHR-1501 + SHR-2005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHR-1501 + SHR-2005.

Explore the full profile